Review

Anthelmintics for drug repurposing: Opportunities and challenges

Seyed Ebrahim Alavi *, Hasan Ebrahim Shahmabadi *

Department of Microbiology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

A R T I C L E   I N F O

Article history:
Received 19 February 2021
Accepted 3 April 2021
Available online 16 April 2021

Keywords:
Anthelmintics
Antiparasitic
Cancer
Drug repositioning
Solubility

A B S T R A C T

Drug repositioning is defined as a process to identify a new application for drugs. This approach is critical as it takes advantage of well-known pharmacokinetics, pharmacodynamics, and toxicity profiles of the drugs; thus, the chance of their future failure decreases, and the cost of their development and the required time for their approval are reduced. Anthelmintics, which are antiparasitic drugs, have recently demonstrated promising anticancer effects in vitro and in vivo. This literature review focuses on the potential of anthelmintics for repositioning in the treatment of cancers. It also discusses their pharmacokinetics and pharmacodynamics as antiparasitic drugs, proposed anticancer mechanisms, present development conditions, challenges in cancer therapy, and strategies to overcome these challenges.

© 2021 The Authors. Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Contents

1. Introduction ................................................................. 435
2. Physicochemical properties of anthelmintics ......................................................... 435
  2.1. Pharmacokinetics and pharmacodynamic ......................................................... 435
      2.1.1. Metabolism and excretion ................................................................. 436
3. Efficacy and spectra of activity of anthelmintics ........................................................ 436
  3.1. Benzimidazoles and pro-benzimidazoles .......................................................... 436
  3.2. Imidazothiazoles and tetrahydropyrimidines ..................................................... 437
  3.3. Macrocyclic lactones ...................................................................................... 437
4. Mode of action as anti-cancer agents ................................................................... 437
  4.1. Anthelmintics under clinical trials ................................................................. 437
      4.1.1. Albendazole ...................................................................................... 437
      4.1.2. Ivermectin ...................................................................................... 437
      4.1.3. Levamisole ...................................................................................... 438
      4.1.4. Mebendazole ................................................................................... 439
      4.1.5. Niclosamide ..................................................................................... 439
  4.2. Anthelmintics with promising anti-cancer effects .............................................. 439
      4.2.1. Flubendazole ................................................................................... 439
      4.2.2. Rafinoxide ...................................................................................... 439
      4.2.3. Nitazoxanide ................................................................................... 439
      4.2.4. Praziquantel .................................................................................... 440

* Corresponding authors.
E-mail addresses: s.ebrahimalavi@gmail.com (S.E. Alavi), ebrahimi@rums.ac.ir (H. Ebrahim Shahmabadi).

Peer review under responsibility of King Saud University.

Production and hosting by Elsevier

https://doi.org/10.1016/j.jsps.2021.04.004

1319-0164/© 2021 The Authors. Published by Elsevier B.V. on behalf of King Saud University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Cancer, with rapidly increasing incidence (18.1 million new cases and annual incidence of 3–5%, 2018) and mortality (9.6 million patients, 2018), is one of the most critical health issues throughout the world (Hassankhani, Rahmani, Taleghani, Sanaat, & Dehghannezhad, 2020; J. Zhang et al., 2019). Many efforts have been made to develop anti-cancer agents, and various lead candidates have been developed at preclinical and clinical stages; however, only 5% of compounds that enter phase I clinical trials receive the end approval (G. Liu et al., 2015).

Generally, to develop a novel anti-neoplastic agent, various natural-based compounds derived from microorganisms, animals, and plants are evaluated by a variety of pharmacological and biochemical analyses, that often continue with the whole chemical synthesis or modification of determined individual compounds (Čaňová, Rozkýdalová, & Rudolf, 2017). Further, this process of drug development has been complemented by screening the assays of libraries of all recognized and determined compounds to select the potentially appropriate candidates for further assessment. However, these strategies are associated with several difficulties, such as financial burden, laboriousness, and longer duration for drug development (Čaňová et al., 2017). Currently, the development of a new drug takes 10–15 years, and the success rate is negligible (approximately 2%). As the cost of clinical trials increases, the development of a new drug takes 10–15 years, and the success rate is negligible (approximately 2%). As the cost of clinical trials increases, the development of a new drug takes 10–15 years, and the success rate is negligible (approximately 2%).

2. Physicochemical properties of anthelmintics

Anthelmintics are a series of compounds, demonstrating anti-infectious activity against helminths, which settle in the human intestine (Laudisi et al., 2020). These therapeutics were initially developed for the treatment of veterinary parasites and have subsequently been used for patients, suffering from helminthiasis. Anthelmintics have a variety of chemical entities and function through changing the parasite (worm) metabolism or paralyzing the parasite, in which the parasite can be eliminated by the host immune system (Laudisi et al., 2020; Rajagopal et al., 2019). It has been demonstrated that some of the anthelmintics are able to inhibit critical oncogenic pathways, such as Wnt/β-catenin, signal transducer and activator of transcription proteins 3 (STAT3), and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) (Laudisi et al., 2020); therefore, their application for cancer treatment has been considered.

This literature review provides an overview of the updated information about anthelmintics with anti-cancer activity and their possible use as anti-cancer agents (i.e., repositioned drugs). These anthelmintics are characterized, in terms of their i) structural analysis, ii) tumor type-specific effects, iii) mode of action, and iv) up to date data about the clinical trials. It also discusses the challenges for their applications as anti-cancer agents, such as low water solubility and low bioavailability, and strategies to overcome these challenges, such as nanocarrier-based formulations, pro-drug formulations, and solid dispersions (SDs).

2.1. Pharmacokinetics and pharmacodynamics

According to chemical structures and pharmacological properties, there are seven classes of modern anthelmintics, including benzimidazoles (BZDs; cambendazole, parbendazole, thiabendazole, mebendazole, fenbendazole, oxefendazole, oxibendazole, albendazole, riconbendazole, and triclabendazole), pro-benzimidazoles (pro-BZDs; netobimin, febantel, and thiophanate), tetrahydropyrimidines (THPs; pyrantel pamoate, pyrantel tartrate, and morantel), imidazothiazoles (IMTs; levamisole), iso-quinolines, salicylanilides (closantel, niclosamide, and rafoxanide), and macrocyclic lactones (MLs, avermectins and milbemycins or endectocides; ivermectin, abamectin, moxidectin, doramectin, eprinomectin, selamectin, and milbemycin oxime) (Barbosa, Löbenberg, de Araujo, & Bou-Chacra, 2019; Gökbultu & McKellar, 2018).

4.2.5. Pyrvinium pamoate ............................................................. 440
4.2.6. Piperazine ........................................................................ 440
4.2.7. Eprinomectin ................................................................. 440

5. Challenges with anthelmintics in cancer therapy ........................................ 440
6. Strategies to overcome these challenges ..................................................... 441
6.1. Nanoparticles for improving the solubility of anthelmintics ................. 441
6.2. Pro-drug formulations .................................................................. 441
6.3. Production of solid dispersions ....................................................... 441
7. Conclusion and future perspectives ............................................................. 443
Funding .............................................................................................. 443
Declaration of Competing Interest ............................................................... 443
References ......................................................................................... 443

References

Avery, M., & Dehghannezhad, 2020; J. Zhang et al., 2019. Many efforts have been made to develop anti-cancer agents, and various lead candidates have been developed at preclinical and clinical stages; however, only 5% of compounds that enter phase I clinical trials receive the end approval (G. Liu et al., 2015). Further, this process of drug development has been complemented by screening the assays of libraries of all recognized and determined compounds to select the potentially appropriate candidates for further assessment. However, these strategies are associated with several difficulties, such as financial burden, laboriousness, and longer duration for drug development (Čaňová et al., 2017). Currently, the development of a new drug takes 10–15 years, and the success rate is negligible (approximately 2%). As the cost of clinical trials increases, the development of a new drug takes 10–15 years, and the success rate is negligible (approximately 2%).

Generally, to develop a novel anti-neoplastic agent, various natural-based compounds derived from microorganisms, animals, and plants are evaluated by a variety of pharmacological and biochemical analyses, that often continue with the whole chemical synthesis or modification of determined individual compounds (Čaňová, Rozkýdalová, & Rudolf, 2017). Further, this process of drug development has been complemented by screening the assays of libraries of all recognized and determined compounds to select the potentially appropriate candidates for further assessment. However, these strategies are associated with several difficulties, such as financial burden, laboriousness, and longer duration for drug development (Čaňová et al., 2017). Currently, the development of a new drug takes 10–15 years, and the success rate is negligible (approximately 2%). As the cost of clinical trials increases, the development of a new drug takes 10–15 years, and the success rate is negligible (approximately 2%).

Anthelmintics are a series of compounds, demonstrating anti-infectious activity against helminths, which settle in the human intestine (Laudisi et al., 2020). These therapeutics were initially developed for the treatment of veterinary parasites and have subsequently been used for patients, suffering from helminthiasis. Anthelmintics have a variety of chemical entities and function through changing the parasite (worm) metabolism or paralyzing the parasite, in which the parasite can be eliminated by the host immune system (Laudisi et al., 2020; Rajagopal et al., 2019). It has been demonstrated that some of the anthelmintics are able to inhibit critical oncogenic pathways, such as Wnt/β-catenin, signal transducer and activator of transcription proteins 3 (STAT3), and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) (Laudisi et al., 2020); therefore, their application for cancer treatment has been considered.

This literature review provides an overview of the updated information about anthelmintics with anti-cancer activity and their possible use as anti-cancer agents (i.e., repositioned drugs). These anthelmintics are characterized, in terms of their i) structural analysis, ii) tumor type-specific effects, iii) mode of action, and iv) up to date data about the clinical trials. It also discusses the challenges for their applications as anti-cancer agents, such as low water solubility and low bioavailability, and strategies to overcome these challenges, such as nanocarrier-based formulations, pro-drug formulations, and solid dispersions (SDs).
The pharmacokinetics of anthelmintics, including their absorption, distribution, and biotransformation/elimination pattern, are critical factors, which determine the time to a maximum effect-site concentration of the drugs (anti-parasitic) in the body. Pharmacokinetics, as a determinant factor for drug exposure in the parasitic location, are strongly correlated with pharmacodynamics (drug effect) (Lanusse et al., 2018). Anthelmintics are administered by oral drench (as a general route), slow-release bolus, injection, or in-feed (Taylor, 1999).

According to previous studies (Davis et al., 2020; Lalthanpuii & Lalchhandama, 2020), transcuticular/tegumental diffusion is an appropriate route for drug entrance into parasitic worms. Drug entrance into the parasite is determined by drug lipophilicity, as a critical physicochemical factor, in which by increasing the drug lipophilicity, a higher amount of the drug can be penetrated and consequently accumulated within the parasite (Lifschitz, Lanusse, & Alvarez, 2017). Therefore, drug entrance and accumulation into a parasitic worm are crucial factors to achieve the optimal therapeutic outcome. Also, other factors, such as i) the balance among drug entry (influx), ii) the capacity of the parasite to metabolize and inactivate the drug, and iii) the drug efflux capacity of the parasite, determine the drug accumulation within a parasite (Lanusse, Lifschitz, & Alvarez, 2015). The exposure time of parasite to active drug concentrations is a critical factor that affects the efficacy and/or durability of activity of most anthelmintics used in ruminants. Overall, these factors are responsible to determine the ultimate anthelmintic activity (Lanusse et al., 2018).

2.1.1. Metabolism and excretion

2.1.1.1. Benzimidazoles and pro-benzimidazoles. Ricobendazole is the active metabolite of albendazole and the only available injectable BZD. In the host body, the gastrointestinal microflora and liver are responsible to metabolize pro-BZDs into active BZD drugs, in which febantel, thiophanate, and netobimin are metabolized into fenbendazole, luxabendazole, and albendazole, respectively (Gokbulut & McKellar, 2018). BZDs are metabolized in the liver to various molecules, such as albendazole sulfoxide and albendazole sulfone for albendazole (Yang, Liu, Chen, & Zhihua, 2016).

Hydroxylation is one of the crucial metabolic pathways of BZDs. In sheep, it has been shown that hydroxy oxendazole and hydroxy fenbendazole were the main hepatic metabolites of fenbendazole following intraruminal administration that are excreted through the bile as free or conjugated metabolites (Gokbulut & McKellar, 2018).

2.1.1.2. Imidazothiazoles and tetrahydropyrimidines. Levamisole is metabolized in the liver and kidney into several components, such as aminorex, and mostly excreted via the kidneys. Depending on the animal species, it has a plasma elimination half-life of 5–6 h (Handley, Belsey, Couchman, & Flanagan, 2019; Kolanović et al., 2018). Pyrantel is mostly metabolized into metabolites with higher polarity in various animals through different metabolic pathways, including the oxidation of the thiophene ring, the oxidation of the tetra-pyrimidine ring, and conjugation to mercapturic acid. The polar metabolites of pyrantel are supposed to be eliminated by the kidneys (Gokbulut & McKellar, 2018).

2.1.1.3. Macroyclic lactones. MLs are partially metabolized by the animal and are mainly excreted via feces (Tydén, Jansson, & Ringmark, 2019). Ivermectin, as a member of MLs, is metabolized in the liver by the cytochrome P450 system. The blood concentration of the drug reaches the peak 4 h after administration, and after that, the concentration decreases slowly. The metabolites concentration in the blood increases for a longer time when it is compared with the parent compound, which can be resulted from the hetero-hepatic recycling. The drug can be detected in various sites, including the nodules, and subcutaneous fascia. A single oral dose (12 mg) of ivermectin reaches the peak 8 h after administration in various sites, such as sebum, and forehead, and starts to decrease after 24 h (El-Saber Batiha et al., 2020).

2.1.1.4. Other anthelmintics. Closantel

Closantel is a salicylanilide compound and normally used for veterinary purposes (Gokbulut & McKellar, 2018; Venkatesh, Pereira, Aseem, & Yadav, 2019). It is poorly metabolized, in which around 80% of the administered dose is eliminated through the feces. Approximately 45% of the orally administered dose is excrated 48 h after administration; however, this value for intramuscular injection is approximately 10%. Closantel has an elimination half-life of 2–3 weeks. In dairy cows, approximately 1% of the administered dose is eliminated through the milk without any change (Venkatesh et al., 2019).

Praziquantel

Praziquantel is an isoquinoline compound, and while in laboratory animals, it is metabolized to glucuronide and sulfuric conjugates, which are less active compared to the parent compound. In human, the absorption of praziquantel occurs quickly and mostly (90%) after administration and then quickly eliminated with a plasma clearance equal to 28 L/kg (Gokbulut & McKellar, 2018).

Trichlorfon

Trichlorfon is an organophosphate that is quickly absorbed after oral administration. It is metabolized in the liver by phosphatases in a host species-specific manner, and the metabolites are then eliminated through the urine (Gokbulut & McKellar, 2018).

Piperazine

Piperazine is a hexahydropyrazine compound. It is absorbed slightly and variably from the gastrointestinal tract, and probably the un-absorbed drug from the gastrointestinal tract is responsible for anti-parasitic activity (Gokbulut & McKellar, 2018).

3. Efficacy and spectra of activity of anthelmintics

Anthelmintics were primarily generated for the treatment of veterinary parasites, and their application has then been expanded for the treatment of human patients. They have a variety of chemical entities and act through several modes of action. For example, BZDs are bound selectively to β-tubulin of nematodes, cestodes, and fluke and block the formation of microtubule and cell division (Hamilton & Rath, 2017). Mebendazole and flubendazole, two members of BZDs, cause the loss of cytoplasmic microtubules of helminths, resulting in the loss of transport of secretory vesicles, a decrease in the uptake of glucose, and an increase in the use of stored glycogen (Hamilton & Rath, 2017). The salicylanilides drugs, such as rafoxanide, oxyxolizonide, and closantel, are proton ionophores (Hamilton & Rath, 2017; Hu et al., 2013) or proton carriers to help to transfer protons from the aqueous phase into the lipophilic membrane (Mahmoud, Saad, Elzanfaly, Amer, & Essam, 2020). Other anthelmintics are functionally classified as nicotinic, glutamate-gated chloride channel potentiators, or macrocides (Hamilton & Rath, 2017).

3.1. Benzimidazoles and pro-benzimidazoles

BZDs demonstrate a significant difference, in terms of efficacy, against various species of parasites (Gokbulut & McKellar, 2018). In various studies, the efficacy of these drugs was evaluated against various types of gastrointestinal nematodes, such as Strongylus species and Parascaris species (Salem et al., 2020; Yuriad,
and levamisole receiver groups, respectively. The results demonstrated that oxfendazole was completely effective (100%) to kill Strongylus and Parascaris worms. Salem et al. (Salem et al., 2020), in another study, investigated the efficacy of fenbendazole on the prevalence of gastrointestinal nematode infections in working horses to measure the resistance of strongyle to the drug using faecal egg count reduction testing (FECRT). The results demonstrated that the drug was highly potent, in which the Strongyle FECR was found to be 100%.

3.2. Imidazothiazoles and tetrahydropyrimidines

Regarding the anti-parasitic effects of pyrantel pamoate, it has been demonstrated that this drug is a potent anthelmintic drug against Strongylus worms (Yuriadi et al., 2019), in which an oral dose of the drug (20 mg/kg) caused a reduction in the eggs per gram (EPG) of feces to zero for Strongylus worms, 12 days after administration in horses. It also demonstrated 95–97% potency against adult cyathostominis, Parascaris equorum, and Strongylus vulgaris, and moderate antiparasitic effects towards Strongylus edentatus (70%) and Oxyuris equi (65%, a gastrointestinal parasite) (Gokbulut & McKellar, 2018). Also, the oral administration of pyrantel pamoate, as a paste formulation and at a dosage of 13.2 mg/kg, caused the parasitidal activity of 95–98% against mature infections of Anoplocephala perfoliata (a tapeworm in equids) in horses and ponies (Slocombe, 2004). Hamed et al. (Hamed, El-Allawy, & Hassnein, 2019) evaluated the anti-parasitic potency of pyrantel (single dose, oral administration, 1 g/10 kg) in parasite-infected donkeys using EPG of feces. The egg count was performed on days 7, 14, 21, and 28 after the drug administration. The results demonstrated that the mean EPG in pyrantel treated animals was less than 90% throughout 28 days of the treatment.

3.3. Macrocyclic lactones

MLs are one of the most favorite anthelmintics, used to control parasitic worms and arthropods of domestic animals and livestock (Yilmaz, Gerst, McKay-Demeler, & Krücken, 2019). Of these compounds, moxidectin was found significantly potent towards equine nematodes (Gokbulut & McKellar, 2018). Katre et al. (Radha Katre, 2020) evaluated the efficacy of ivermectin and moxidectin against gastrointestinal nematode (Strongylus species. and Parascaris species) infection in horses using faecal egg count (FEC). The horses received a single oral dose of ivermectin (0.2 mg/kg) and moxidectin (0.4 mg/kg). The results demonstrated that both the drugs caused a reduction in the FEC for both the parasites by 100% on the 14th-day post-treatment. However, the FEC was more rapidly reduced in moxidectin receiver horses compared to those received ivermectin (Radha Katre, 2020). In the other study, Shashank et al. (Shashank & Ayodhya, 2019) evaluated the efficacy of ivermectin against goats positive for gastrointestinal nematodal infestation and compared the results with levamisole using the FEC method. FEC, at day 0, was 1520 ± 156.20 and 1310 ± 126.88 in ivermectin and levamisole receiver groups, respectively. The Strongyles, Trichuris, and Strongyloides species were the gastrointestinal nematodes that are recognized in these animals. The results of the evaluation demonstrated that ivermectin caused a reduction of 86.22, 100 and 100% on day 3, 5 and 7 post-treatment, respectively, in FEC, while these values for levamisole were 77.38, 97.20, and 100%, respectively. The study suggested that ivermectin could be an ideal anthelmintic drug against both single and mixed gastrointestinal nematodal infestation in goats.

4. Mode of action as anti-cancer agents

Anthelmintics have exerted anti-cancer activity against various types of cancers, in particular cancer stem cell-like subpopulations (Hamilton & Rath, 2017). The anti-cancer activities of mebendazole, pyrvinium pamoate, and niclosamide were reported by Mukhopadhyay et al. (Mukhopadhyay, Sasaki, Ramesh, & Roth, 2002), in 2002, Esumi et al. (Esumi, Lu, Kurashima, & Hanako, 2004), in 2004, and Wang et al. (Wang et al., 2009), in 2009, respectively. Since then, several studies (Ashburn & Thor, 2004; Pantziarka et al., 2014) have demonstrated that anthelmintics could exert anti-cancer effects in vitro, in vivo, and in first clinical trials. Various mechanisms, such as down-regulating the P-glycoprotein (P-gp) expression via the inhibition of the epidermal growth factor receptor (EGFR) (Armando et al., 2020), the disruption of microtubule polymerization, the induction of apoptosis, inhibition of cell cycle progression (G2/M), anti-angiogenesis, the blockage of the transport of glucose, and uncoupling the oxidative phosphorylation in mitochondria (Barbosa et al., 2019; Son, Lee, & Adunyah, 2020), have been identified for the anti-cancer activity of anthelmintics (Fig. 1) (Armando et al., 2020; Son et al., 2020). Overall, anthelmintics can be divided into two groups; those progressed in clinical trials (Table 1) and others that are not.

4.1. Anthelmintics under clinical trials

4.1.1. Albendazole

Albendazole has demonstrated in vitro anti-tumor effect against hepatocellular carcinoma (HCC) and colorectal carcinoma (CRC) and in vivo anti-tumor effect against a xenograft model of peritoneal carcinomatosis. This drug has also shown anti-proliferative activity against tumor cells (e.g., leukemia and ovarian cancer cells) which are resistant to other microtubule-targeted drugs (Armando et al., 2020). In addition to interfering in microtubule function, albendazole seems to inhibit the production of vascular endothelial growth factor (VEGF) and angiogenesis in the peritoneal ovarian tumor in animal model (mice) (Armando et al., 2020; Pourgholami, Cai, Lu, Wang, & Morris, 2006). Currently, the anti-cancer effect of albendazole is being investigated in a clinical trial (clinical trial no. NCT02366884) (Table 1).

4.1.2. Ivermectin

Ivermectin exerts its anti-parasitic effects by increasing the parasite cell membrane permeability, resulting in paralysis and death. It has also demonstrated some preliminary anti-cancer effects (Armando et al., 2020). Ivermectin can inhibit proliferation, metastasis, and angiogenic activity in various tumor and cancer cells. These activities may result from its ability to regulate various signaling pathways through p21-activated kinase 1. Also, ivermectin helps programmed cell death, such as apoptosis, autophagy, and pyroptosis. In addition, it is capable of sensitizing multidrug-resistant cells to chemotherapeutics and causes an optimal effect when used in combination with other chemotherapeutics (Tang et al., 2020). Jiang et al. (Jiang, Wang, Sun, & Wu, 2019) demonstrated that ivermectin was potent to reverse the resistance of tumor cells to anti-cancer drugs. The drug functions mainly by reducing the P-gp expression through the inhibition of the EGFR. Ivermectin inhibits ERK/Akt/NFκB pathway through binding to the extracellular domain of EGFR and inhibiting its activation. The restriction of NF-κB causes a reduction of P-gp transcription. Ivermectin also causes the restriction of yes associated protein 1 (YAP1), which functions as the transcription activator for those genes related to cell proliferation and suppression of apoptosis (Armando et al., 2020). Moreover, ivermectin blocks the karyopherin β1 (KPNB1, encoding nuclear transport factors) function.

4.1.3. Moxidectin

Moxidectin has demonstrated anti-cancer activities in various tumor models, such as colon cancer (using HCT-116 cell line) and breast cancer (using MCF-7 cell line) (Armando et al., 2020). It has demonstrated the ability to inhibit proliferation, induce apoptosis, and angiogenesis, as well as block the microtubule polymerization. Moxidectin has also shown anti-cancer activity against various tumor models in combination with other chemotherapeutics, such as doxorubicin and gemcitabine (Jiang et al., 2019). In a clinical trial (clinical trial no. NCT04086247), ivermectin and moxidectin were found to be safe and efficacious in treating patients with advanced cancer.
Kodama et al. (Kodama et al., 2017) demonstrated that ivermectin inhibited the function of KPNB1 in ovarian cancer cells, resulting in apoptosis and cell cycle arrest. Ivermectin, in combination with paclitaxel, caused synergistic anti-cancer effects in vivo (Kodama et al., 2017). Ivermectin can also inhibit the canonical wnt (wingless-related integration site) signaling pathway that influences a transcriptional factor of the T-cell factor (TCF) family, resulting in the inhibition of colon and lung cancer proliferation (Armando et al., 2020). Ivermectin is also able to modulate those genes involved in the epithelial mesenchymal transition and maintenance of a cancer stem cell (CSC) phenotype in triple-negative breast cancer (TNBC), and consequently causes dysfunction in clonogenic self renewal in vitro, and the restriction of tumor growth and metastasis in vivo (Kwon et al., 2015). In addition, ivermectin can cause anti-tumor effects through a variety of mechanisms. It can interact with various targets, such as multidrug resistance (MDR) protein (Juarez, Schcolnik-Cabrera, & Dueñas-Gonzalez, 2018).

4.1.3. Levamisole

Levamisole has been identified with various functions, such as anti-tumor activity (Qiao et al., 2020). In particular, it is used as an adjuvant of 5-fluorouracil (5-FU) and in combination with 5-FU for the treatment of colon cancer (stage III) (Qiao et al., 2020). Costa e Silve et al. (Costa, Celani, Azevedo, & Medeiros, 2019) compared the efficacy of levamisole with cisplatin in the treatment of

| Drug          | Phase     | Type of cancer                                                                 | Study ID number or reference |
|---------------|-----------|--------------------------------------------------------------------------------|------------------------------|
| Albendazole   | II        | Colorectal cancer, leukemia, liver and ovarian cancers                           | NCT02366884                  |
| Ivermectin    | II        | triple-negative breast cancer, colorectal cancer, lung and ovarian cancers       | NCT02366884                  |
| Levamisole    | III       | Hepatocellular carcinoma                                                       | NCT03950518                  |
| Levamisole    | III       | Intrahepatic cholangiocarcinoma                                                 | NCT03940378                  |
| Mebendazole   | III       | Colon cancer                                                                   | NCT03925662                  |
| Mebendazole   | Terminated (lack of effect)          | Gastrointestinal cancer                                                        | NCT03628079                  |
| Mebendazole   | II        | Colorectal cancer                                                              | NCT03925662                  |
| Niclosamide   | Terminated (low accrual)             | Colorectal cancer                                                              | NCT02687009                  |
| Niclosamide   | II        | Colorectal cancer                                                              | NCT02519582                  |
| Niclosamide   | II        | Familial adenomatous polyposis                                                  | NCT04296851                  |
| Niclosamide   | II        | Tumors of neuroendocrine origin, lung cancer (non small cell), breast cancer     | NCT02807805                  |
|               |           | (triple-negative), acute myeloid leukemia, osteosarcoma, adrenocortical carcinoma, glioma tumors, ovarian, prostate, lung, and head and neck cancers |                              |
urethane-induced lung tumors in rats using ex vivo fluorescence imaging. The results demonstrated that while the mean fluorescence intensity (MFI) was 245 ± 15 in the levamisole treated group, this value was 277 ± 28 in the animals receiving cisplatin. The MFI in the saline-treated group was 680 ± 57, which was considerably higher than that in the other groups (p < 0.05). The results of the study demonstrated that levamisole had a positive effect on the treatment of urethane-induced lung tumors in rats (Costa et al., 2019). Qiao et al. (Qiao et al., 2020) assessed the anti-cancer effects of levamisole in lung cancer, both in vitro and in vivo, and the results demonstrated that levamisole caused a reduction in the proliferation of lung cancer cells and inhibited the cell cycle arrest in G0/G1 phase. Also, levamisole caused an increase in the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced death receptor 4 (DR4)-independent apoptosis rate through the restriction of the phosphorylation of c-Jun N-terminal kinase (JNK). In addition, it was found that levamisole caused an increase in the expression of LC3B (a component of LC3B-DR4/Erk as a cellular protective pathway) and subsequently activated the phosphorylation of Erk and increased the DR4 expression. Currently, levamisole has been evaluated in two clinical trials (phase III), in terms of efficacy and safety. The first trial is evaluating the therapeutic effects of levamisole in combination with arginine hydrochloride in the patients, suffering from advanced hepatocellular carcinoma (HCC) (NCT03950518). The second one is assessing levamisole hydrochloride for the treatment advanced intrahepatic cholangiocarcinoma (NCT03940378) (Laudisi et al., 2020).

4.1.4. Mebendazole

Mebendazole can be an appropriate repositioned drug as it has a proper and proven toxicity profile and pharmacokinetics, making the drug suitable for therapeutic purposes. Also, it is an inexpensive drug that can be administered easily. Mebendazole causes the inhibition of various factors contributing to tumor progressions (e.g., polymerization of tubulin, angiogenesis, pro-survival pathways, and matrix metalloproteinases). Mebendazole causes direct cytotoxic effects, has synergistic effects with ionizing radiations and various chemotherapeutics, and motivates anti-tumoral immune responses. Mebendazole, as a single agent or in combination with chemotherapeutics, causes a reduction or complete inhibition of tumor growth, a significant decrease in the metastatic spread, and an increase in survival time (Guerini et al., 2019). The therapeutic effects of mebendazole against various cancers have been demonstrated in various studies (X.-h. Chen et al., 2019; L. Zhang et al., 2019). Chen et al. (X.-h. Chen et al., 2019) demonstrated that mebendazole caused the induction of apoptosis in c-Maf (a vital oncogenic transcription factor that participates in myelomagenesis)-expressing myeloma cells. Also, an oral dose of the drug caused a delay in the growth of human myeloma xenografts (nude mice) without inducing any evident toxicity. Zhang et al. (L. Zhang et al., 2019) showed that mebendazole, at the concentration of 0.7 μM, was potent to inhibit the mammosome formation from non-sorted cells in two human breast cancer SUM159PT and MDA-MB-231 cells by approximately 86 and 88%, respectively, compared to the control group. At present, mebendazole is in progress in various phases of clinical trials (II and III) for the treatment of different cancers, including colon cancer and CRC (NCT03925662).

4.1.5. Niclosamide

The mechanism of action of niclosamide against parasites comprises uncoupling the oxidative phosphorylation in mitochondria, resulting in a disruption in the metabolism of parasites (Barbosa et al., 2019). MacDonald et al. (MacDonald et al., 2006) may be the first who identified the probable repositioning of niclosamide for cancers when observed unexpected results for this drug. They evaluated protein–protein interactions in human embryonic kidney 293 (HEK-293) cells using protein-fragment complementation assays (PCA) to detect hidden or not expected biological functions from a wide variety of compounds, belonging to various therapeutic categories. PCA can identify unexpected anti-proliferative effects when using niclosamide, observed in various types of cancer cells, including a human prostate cancer cell (PC-3) (Samy et al., 2020), a human lung cancer cell (A549) ( Özdemir, Turanlı, Çalışkan, Arka, & Banoglu, 2020), a human pancreatic cancer cell (MiaPaCa) (Lee, Lee, Sim, & Kim, 2020), a human colon cancer cell (LOVO) (Lee et al., 2020), and a human glioblastoma cell (U87MG) (Arzani et al., 2019), with an inhibitory concentration of 50 (% IC50) at the mean concentrations of 0.6 μM (MacDonald et al., 2006). Since then, various preclinical studies (L. Chen, Wang, Shen, Lin, & Li, 2017; Suliman et al., 2016; Zhou, Jin, Jin, Liu, & Pan, 2017) demonstrated that niclosamide exerts its anti-cancer effects through the inhibition of signaling pathways, including NOTCH, NF-κB, and mammalian target of rapamycin (mTOR). In addition, the potency of the drug to inhibit other oncogenic pathways, such as Wnt/β-catenin, STAT3, and MEK1/2-ERK1/2, has been demonstrated against various types of cancer cells, such as esophageal, ovarian, and melanoma, in several preclinical studies (Shangguan et al., 2020; Wei, Liu, Yuan, & Yao, 2020; Zhu et al., 2019). Currently, the anti-cancer effects of niclosamide have been evaluated in several clinical trials (NCT02687009, NCT02519582, NCT04296851, and NCT02807805).

4.2. Anthelmintics with promising anti-cancer effects

4.2.1. Flubendazole

Flubendazole has demonstrated anti-tumor effects against various cancer cells, including leukemia, neuroblastoma, multiple myeloma, melanoma, and breast cancer cells (Armando et al., 2020; Hou et al., 2015). It functions through i) the induction of changes in microtubule structure, ii) the induction of apoptosis, iii) the restriction of angiogenesis, iv) the induction of cell differentiation, v) the restriction of cell migration, and vi) the induction of reactive oxygen species (ROS) activating autophagy (Armando et al., 2020; Hou et al., 2015). Currently, there are no clinical trials considering the anti-tumor effects of flubendazole against human malignancies (Armando et al., 2020).

4.2.2. Rafoxanide

Rafoxanide is a halogenated salicylanilide and can effectively inhibit the oncopgenic BRAF V600E mutant protein, prevalently developed in melanomas and CRCs, and linked with a poorer prognosis (Laudisi et al., 2020). While it restricts the proliferation of CRC cells, it has no effects on normal colonic epithelial cells. Rafoxanide down-regulates the expression of cyclin D1 protein and causes cell accumulation in the G0/G1 phase. These processes depend upon the selective induction of the endoplasmic reticulum stress response, resulting in caspase-dependent cell death (Grazia et al., 2020). Also, it has been found that rafoxanide inhibits the proliferation of human gastric cancer SGC-7901 and BGC-823 cells in vitro via the restriction of the activity of the PI3K/Akt/mTOR signaling pathway. This process induces autophagy and apoptosis in cancerous cells (Liu et al., 2019).

4.2.3. Nitazoxanide

The anti-cancer effects of nitazoxanide have been reported against various cancers, such as ovarian and colon cancers (Laudisi et al., 2020; Pal, Nandave, & Kaithwas, 2020). Nitazoxanide has exceptional pharmacokinetic and safety profiles. It can cause CRC cells apoptosis in a glutathione-S-transferase P1 (GSTP1)-dependent manner. In HCT-116 and HT-29-derived spheroids, nitazoxanide caused a reduction in c-Myc, mTOR, and Wnt signaling

Seyed Ebrahim Alavi and H. Ebrahimii Shahmabadi

Saudi Pharmaceutical Journal 29 (2021) 434–445
pathways (0.1–17 μM), while it activated the AMPK pathway. These findings were confirmed in vivo, where nitazoxanide (100 mg/kg), in combination with irinotecan (40 mg/kg), induced a strong suppression in the tumor growth of a human xenograft colorectal cancer in NMRI nu/nu mice compared to irinotecan alone (Laudisi et al., 2020). It has been demonstrated that, in breast cancer xenograft mouse models, nitazoxanide functions through various pathways, such as AMPK, mTOR, and Wnt signaling. Also, in these models, nitazoxanide acts through the downregulation of c-Myc (Pal et al., 2020). Pal et al. (Pal et al., 2020), in one study, evaluated the anti-cancer effects of nitazoxanide (50 mg/kg) compared to those of tamoxifen (tamoxifen) against mammary gland carcinoma induced by N-methyl-N-nitrosourea (MNU) in experimental rats. The results demonstrated that nitazoxanide restored the histological architecture in the animals and caused a reduction in the alveolar buds and a downregulation in the oxidative stress markers, such as glutathione, protein carbonyl, and catalase, and inflammatory markers, such as nitric oxide, hydrogen sulphide, cyclooxygenase, and lipooxygenase. The results suggested that nitazoxanide could be exploited as a potential chemoprophylactic agent against mammary gland carcinoma developed by MNU.

4.2.4. Praziquantel
Praziquantel is an anthelmintic drug, and its function has not yet been well understood; however, it can function through the blockade of Ca2+ channels, resulting in an increase in the intracellular concentration of Ca2+ and the induction of muscular contractions (Dattilo et al., 2020). Dattilo et al. (Dattilo et al., 2020) demonstrated that praziquantel at the concentration of 20–40 μM can increase the cytotoxicity of paclitaxel. Especially, praziquantel in combination with paclitaxel can synergistically inhibit cell proliferation and causes apoptosis in various cancer cells, such as CRC DLD-1 (Laudisi et al., 2020). Praziquantel in combination with paclitaxel is also able to impair the X-linked inhibitor of apoptosis protein (XIAP) expression as an anti-apoptotic protein, that functions as an effective inhibitor of caspase activity (Laudisi et al., 2020).

4.2.5. Pyrvinium pamoate
Pyrvinium pamoate is able to kill various cancer cells, especially CSC. The drug functions through the reduction of WNT- and Hedgehog-dependent signaling pathways (Dattilo et al., 2020). It also causes an inhibition in the mitochondria respiration and can inhibit oncogenic PI3K-dependent signaling (Dattilo et al., 2020). Dattilo et al. (Dattilo et al., 2020) demonstrated the anti-cancer effects of pyrvinium pamoate against triple-negative breast CSC that caused a reduction in the metastases of CSC by affecting the lipid anabolism. The drug caused a disruption in the anabolic flux from glucose to cholesterol and fatty acids. Nair et al. (Nair et al., 2020) evaluated the anti-cancer activity of pyrvinium pamoate against human B cell acute lymphoblastic leukemia cells, including REH and RS4. Also, the metabolic function of these cells was evaluated by measuring the rates of extracellular acidification and oxygen consumption. The results demonstrated that pyrvinium pamoate showed anti-leukemia effects against all cell lines with the IC50 of 0.17 and 1 μM for REH and RS4 cells, respectively. Also, the effects of the drug on the REH cell cycle were evaluated, and the results demonstrated a significant reduction in the cell number in the S (by ~26%) and M phases (by ~50%) compared to the control group (Nair et al., 2020). The anti-tumor activity of pyrvinium pamoate was also evaluated in a xenograft model of human pancreatic cancer PANC1 cells (Laudisi et al., 2020). The oral administration of pyrvinium pamoate (100 and 200 mg/kg) caused a reduction in tumor growth and inhibited the Akt phosphorylation. It was found that pyrvinium pamoate (0.1 and 0.3 μM) inhibited the transcriptions of two critical chaperons (i.e. GRP78 and GRP94), thereby restricted the unfolded protein response due to glucose deprivation. The drug also inhibits other UPR pathways (e.g. XBP-1 and ATF4) stimulated by glucose starvation (Laudisi et al., 2020).

4.2.6. Piperazine
The anti-cancer effects of piperazine and its derivatives against various types of cancer cells have been demonstrated in various studies (Evren, Yurttas, Ekselli, & Akalin-Ciftci, 2019; Mongre et al., 2019). The piperazine derivative AK301 at the concentration of 5 μM could cause a critical impairment in the tubulin polymerization and a mitotic arrest in human colorectal adenocarcinoma HT-29 and HCT-116 cells (Laudisi et al., 2020). In parallel, AK301 induced the expression of tumor necrosis factor receptor 1 (TNFR1) therefore caused an increase in the susceptibility of cancer cells to apoptosis by TNF-α (Laudisi et al., 2020). Özdemir et al. ( Özdemir et al., 2020 ) developed a series of benzimidazole-piperazine hybrids and evaluated their toxicity effects against human lung cancer A549 and human breast cancer MCF-7 cells. The results demonstrated that most of the hybrids had anti-proliferative activity against A549 cells with the IC50 of 2.8–7.8 μM. Also, one compound demonstrated the most balanced cytotoxicity effect towards A549 and MCF-7 cells with the IC50 of 5.4 and 4.2 μM, respectively. Mechanistically, these compounds caused a cleavage in PARP-1 and activate caspase 7, resulting in morphological changes, such as bleb formation in the treated cells, and a significant increase in the nuclear fragmentation. Considering all the results, these findings demonstrate that these compounds (benzimidazole-piperazine hybrids) exert their cytotoxicity through the apoptotic cell death induction ( Özdemir et al., 2020 ).

4.2.7. Eprinomectin
Eprinomectin is a member of avermectin drugs, demonstrating exceptional broad-spectrum anti-parasitic activity. Samy et al. ( Samy et al., 2020 ) evaluated its anti-cancer effects against PC-3 cells. The results demonstrated that eprinomectin caused a significant reduction in PC-3 cell viability as well as suppression in colony formation and wound healing abilities. Eprinomectin exerted its cytotoxicity effects through inducing ROS and the activation of apoptosis. The drug also could affect the cyclin-dependent kinase 4 (CDK4), causing an arrest in the G0/G1 phase of the cell cycle, resulting in the induction in PC-3 cells. Furthermore, eprinomectin could restrain the expression of various markers related to cancer stem cells (e.g. ALDH1, Nanog, and CD44) and pluripotent stem cells (e.g. alkaline phosphatase). In addition, it was found that the drug caused the translocation of β-catenin from the nucleus to the cytoplasm, resulting in the inhibition of Wnt/β-catenin signaling pathway. In addition, the results of western blot analysis displayed that eprinomectin caused a reduction in the expression of the crucial cell cycle (e.g. cyclin D3, and c-Myc) and anti-apoptotic markers (e.g., Mcl-1, XIAP, c-IAP1, and survivin). In contrast, eprinomectin could activate pH2A.X, Bad, caspases 9, and 3. It also caused a cleavage in PARP1. These findings demonstrated that eprinomectin can be considered as a promising compound for the treatment of advanced PCa cells through regulating apoptosis signaling ( Samy et al., 2020 ).

5. Challenges with anthelmintics in cancer therapy
Low water solubility is a problem that limits the use of anthelmintics (P. Li, Rios Coronado, Longstaff, Tarashansky, & Wang, 2018). Drug insolubility can influence both the pharmacokinetic and pharmacodynamic profiles of drugs. The low water solubility of drugs can cause: 1) a reduction in the drug absorption and permeation that in combination with the rapid drug degradation could result in an inadequate in vivo drug concentration and failure to achieve the therapeutic dose and thus the appropriate pharma-
cological effects, and ii) the oscillation in the drug plasma levels that results in the unforeseeable levels of bioavailability. To solve these problems, the dosage forms can be increased; however, increasing the dosage to achieve the therapeutic effects can result in: i) an increase in the costs of treatment, ii) incomplete absorption of the drug in vivo and its removal from the environment, and iii) the emergence of the drug toxicity (Khalikov & Dushkin, 2020). Therefore, the development of strategies to solve these problems-related to anthelmintics is of great importance.

6. Strategies to overcome these challenges

There are various shortcomings in the use of anthelmintics, such as low water solubility and low bioavailability, resulting in a reduction in the potency of these drugs for cancer therapy. To overcome these challenges, various strategies could be suggested as follow that enhance anti-cancer effects of anthelmintics.

6.1. Nanoparticles for improving the solubility of anthelmintics

Nanoparticles are known with high surface to volume ratio, meaning that by reducing the size, the higher surface area is provided (Barbosa et al., 2019). Increasing the surface area causes an increase in the dissolution rate of the particles (Barbosa et al., 2019). Also, nanoparticles take advantage of the ease of surface modification, allowing them to target specific cancer cells, expressing specific surface receptors (Ghaferi, Asadollahzadeh, Akbarzadeh, Ebrahimi Shahmabadi, & Alavi, 2020; Ghaferi, Koohi Moffakhari Esfahani, et al., 2020) (Fig. 2A).

Particle size also impacts the diffusion layer thickness and saturation solubility (Barbosa et al., 2019; Fontana et al., 2018; Peltonen & Hirvonen, 2018). Increased saturation solubility and dissolution rate are the two critical factors of nanoparticles to enhance the drug absorption and bioavailability of the drugs with poor water solubility (Barbosa et al., 2019). Using nanostructures provides various advantages, such as i) drug protection from degradation in the organism, ii) improved drug absorption in tumor tissue, and iii) the modification of the drug pharmacokinetic properties, compared to the free administration of the drugs (Ebrahim Shahmabadi et al., 2014; Ghaferi, Amari, et al., 2020; Vieira & Gamarra, 2016). Also, drug encapsulation into nanoparticles can improve the efficacy of the drug and reduce its side effects (Alavi, Esfahani, Ghassemi, Akbarzadeh, & Hassanshahi, 2014; Alavi, Muflih Al Harthi, Ebrahim Shahmabadi, & Akbarzadeh, 2019). In addition, nanocarrier-based drug delivery systems cause an increase in drug economic life (Movahedi, KOOHI, Alavi, & Akbarzadeh, 2013). Researchers have used various nanocarriers to improve the bioavailability of anthelmintics (Paredes, Llabot, Sanchez Bruni, Allemandi, & Palma, 2016; Rehman, Khan, Khan, Shafique, & Khan, 2018). Rehman et al. (Rehman et al., 2018) synthesized nicosamide-loaded solid lipid nanoparticles (SLNs) and could increase the bioavailability of the drug by 11.1-folds. This finding indicated that the drug absorption significantly increased by taking up SLNs, as a drug delivery system, from the gastrointestinal wall, resulting in an increase in the drug bioavailability. Also, Paredes et al. (Paredes et al., 2016) synthesized self-dispersible nanocrystals of albendazole and could increase the dissolution rate of the drug by 4-fold that could increase the drug bioavailability. Nanocrystals have a very enlarged surface area, which results in a rapid saturation in the dissolution layer around the particles, and as a result an increase in the dissolution rate (Paredes et al., 2016). In addition, Darwish et al. (Darwish, Bayoumi, & El-Koly, 2018) synthesized nitazoxanide-loaded liposome nanoparticles using the membrane extrusion method and evaluated their biodistribution in ehrlich ascites carcinoma-bearing Swiss albino mice using gamma scintillation counter. The results demonstrated a rapid and higher accumulation of the nanoformulation in the tumor sites. This could result from the disruption of lipid bilayer due to the photosensitization process and the singlet oxygen species as a result.

6.2. Pro-drug formulations

Prodrugs are chemically modified drug molecules that are inactive or partially inactive. They are converted to the active parent drug on or near the target site in vivo by chemical and/or enzymatic biotransformation to exert the therapeutic effects (Fig. 3).

The prodrug approach can resolve various unsuitable features, such as poor aqueous solubility, poor oral or local absorption, short half-life, and toxicity (Jornada et al., 2016). There are two major classes of prodrugs, including carrier-linked prodrugs and bioprecursors (Jornada et al., 2016). Carrier-linked prodrugs are composed of a drug linked to a promoiety, which is eliminated through a chemical or enzymatic reaction, leading to the drug release (Jube, Breijyeh, & Karaman, 2020), while bioprecursor prodrugs have no carrier and are quickly converted to an active drug through oxidation or reduction reactions (Jornada et al., 2016; Jube, 2020).

Prodrug design is a powerful tool to improve various properties of drugs, such as solubility, and bioavailability (Sanchez & Ferreira, 2019). Researchers, in various studies (Chassaing et al., 2008; Flores-Ramos et al., 2017; L. Nielsen, Bundgaard, & Falch, 1992; L. S. Nielsen, Slök, & Bundgaard, 1994; Zimmermann et al., 2018), have developed various prodrugs of anthelmintics to improve their aqueous solubility. Nielsen et al. (L. Nielsen et al., 1992) synthesized an N-(4-amino-methylbenzoyl)oxymethyl prodrug of thiabendazole, demonstrating a 300-fold higher water-solubility compared to the parent compound. Nielsen et al. (L. S. Nielsen et al., 1994), in another study, synthesized a prodrug of mebendazole (N-alkoxy carbonyl), which was exceptionally more soluble compared to mebendazole (solubility rate of 2.7 × 10⁻¹⁰ vs. 1.7 × 10⁻⁶ M for the prodrug and mebendazole, respectively). Chassaing et al. (Chassaing et al., 2008) synthesized a highly watersoluble prodrug of fenbendazole, in which its aqueous solubility was extraordinarily increased by 195-fold compared to when the parent drug was used. Also, Flores-Ramos et al. (Flores-Ramos et al., 2017) synthesized a phosphate salt prodrug of triclabendazole (MFR-5) and demonstrated that its water solubility was exceptionally increased by 88000-fold compared to that of the parent compound. In addition, Zimmermann et al. (Zimmermann et al., 2018) synthesized an N substituted prodrug of mebendazole, and the results showed that the prodrug had more than 10000-fold aqueous solubility compared to when mebendazole was used.

6.3. Production of solid dispersions

SDs strategy is a promising approach to improve drug solubility. It is composed of two or more different components, including a hydrophobic drug and a hydrophilic matrix (Fig. 4) (Khalikov & Dushkin, 2020; Wagh & Wagh, 2015).

SDs of drugs are delivery systems for drug molecules and can improve the biopharmaceutical properties of drugs, such as increasing the solubility and bioavailability, decreasing the toxicity, and increasing the stability of the drugs during storage. SDs can increase the drug solubility through the following mechanisms: i) decreasing the size of the particles, ii) improving the wettability, and iii) increasing the level of drug dispersion in a polymeric matrix (Khalikov & Dushkin, 2020). Various SDs, such as disodium salt of glycyrhizic acid (Na2GA) (Meteleva et al., 2019), polyvinylpyrrolidone (Arkhipov et al., 2019), poloxamer 407 (Real, Orzan, Leonardi, & Salomon, 2020), polyethylene...
Fig. 2. Using nanocarriers for improving drug solubility. A poor soluble drug can be loaded into a tumor cell-targeted nanocarrier and administered orally. The nanoformulation is adsorbed through the gastrointestinal tract and deposited into the tumor tissue (e.g., liver tumor) through the Enhanced Permeation and Retention (EPR) effect, resulting from the increased vascular permeability in the tumor tissue (passive mechanism). As the nanoformulation is targeted against tumor cells, it can specifically interact with its specific receptor on the surface of tumor cells and internalized into the cells (active mechanism).

Fig. 3. Using prodrug for improving drug solubility to cross biological barriers. A) Due to low solubility, some drugs cannot cross biological barriers, and as a result, their therapeutic effects cannot be observed or are decreased. B) This shortcoming can be resolved using the prodrug approach (carrier-linked prodrug). C) after crossing the barrier, D) the prodrug is biotransformed, and the active drug is produced in the cell and demonstrates the optimized effect.
glycol-6000 (PEG 6000)/ Poloxamer 188 (P 188) (Dong et al., 2020), and povidone (M. Li et al., 2020), have been used to increase the solubility of anthelmintics. Meteleva et al. (Meteleva et al., 2019) provided an SD of praziquantel using Na2GA and could increase the solubility of the drug by 3.5-folds. Also, Arkhipov et al. (Arkhipov et al., 2019) prepared an SD of fenbendazole using polyvinylpyrrolidone, and the results demonstrated an increase in the drug solubility by 2.8-fold. In another study, Real et al. (Real et al., 2020) provided an SD of triclabendazole using poloxamer 407 that could increase the solubility of triclabendazole by 41.5-fold. In addition, Dong et al. (Dong et al., 2020) prepared an SD of albendazole using PEG 6000/P 188 that increased the solubility of albendazole by 3.3-fold. Li et al. (M. Li et al., 2020), in the other study, synthesized an SD of rafoxanide using povidone, and the results showed an increase in the solubility of the drug by 7000-fold.

7. Conclusion and future perspectives

The drug (approved and abandoned) repositioning is increasingly used as a favorite and cost-effective strategy in oncology. These drugs can reach the clinic more quickly as their safety and pharmacological profiles have already been approved (Sleire et al., 2017). Some of the anthelmintics have shown promising results for cancer therapy. They can be administered as monotherapy or in combination with other anti-cancer drugs to enhance the anti-cancer effects in vitro and in preclinical studies. These drugs have received considerable attention, as they can interfere with key oncogenic pathways. These properties cause some anthelmintics to be undergone clinical trials (phase I/II) for cancer treatment (Laudisi et al., 2020). They are mainly administered orally, resulting in their higher content in the gastrointestinal tract; however, their concentration in the circulation is usually very low mainly due to low water solubility (Khalikov & Dushkin, 2020; Laudisi et al., 2020). In this literature review, we discussed the repositioning of anthelmintics in oncology, and the shortcomings for their success to reach the clinic. As discussed, the main issue that limits their use in vivo is low water solubility, resulting in their low bioavailability. The strategies to overcome these shortcomings (i.e., nanocarriers-based formulation, prodrug design, and SDs) were also discussed. These strategies can be used to improve the solubility, bioavailability, toxicity profile, and the cost-effectiveness of anthelmintics in oncology. However, these need to be optimized, in terms of toxicity profile and safety issues, demanding further studies in future. Overall, the available data have demonstrated that the repositioning of anthelmintics in cancer therapy is a promising approach and can be considered as a less expensive and faster strategy for extending the repository of approved drugs. However, to perform the repositioning, there are some challenges that must be addressed to provide a real conception of whether a repositioning project is a valuable opportunity. Consequently, further studies are required to better understand the pharmacokinetic and dynamic profile of the upcoming formulations in our body. In our opinion, the generation of effective formulations of anthelmintics, as an anti-cancer, might require strong interdisciplinary collaborations between chemists, material scientists, and pharmacists. We hypothesize that listing those anthelmintics that are currently under clinical trial or under investigation in research laboratories with their promising anti-cancer effects as well as their challenges and potential strategies in one place, in this review, will generate a greater interest in anthelmintics and can help to formulate their anti-cancer effective formulations soon.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

Alavi, S.E., Esfahani, M.K.M., Ghassemi, S., Akbarzadeh, A., Hassanshahi, G., 2014. In vitro evaluation of the efficacy of liposomal and pegylated liposomal hydroxyurea. Indian J. Clin. Biochem. 29 (1), 84–88.
Alavi, S. E., Muflih Al Harthi, S., Ebrahimi Shahmabadi, H., & Akbarzadeh, A. (2019). Cisplatin-loaded polybutylcyanoacrylate nanoparticles with improved properties as an anticancer agent. International journal of molecular sciences, 20(7), 1531.
Arkhipov, I.A., Khalikov, S.S., Sadov, K.M., Dushkin, A.V., Meteleva, E.S., Varlamova, A. I., Danilevskaya, N.V., 2019. Influence of mechanochemical technology on anthelmintic efficacy of the supramolecular complex of fenbendazole with polyvinylpyrrolidone. J. Adv. Veterinary Anim. Res. 6 (1), 133.
Armando, R.G., Mengual Gómez, D.L., Gomez, D.E., 2020. New drugs are not enough—drug repositioning in oncology: an update. Int. J. Oncol. 56 (3), 651–684.
Arzani, H., Adabi, M., Mosafej, F., Derkoosh, F., Khosravani, M., Maleki, H., Kamali, M., 2019. Preparation of curcumin-loaded PLGA nanoparticles and investigation of its cytotoxicity effects on human glioblastoma U87MG cells. Biointerface Res. Appl. Chem. 9 (5), 4225–4231.
Ashburn, T.T., Thor, K.B., 2004. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discovery 3 (8), 673–683.
Barbosa, E.J., Löbenberg, R., de Araujo, G.L.B., Bou-Chacra, N.A., 2019. Niclosamide repositioning for treating cancer: Challenges and nano-based drug delivery opportunities. Eur. J. Pharm. Biopharm. 141, 58–69.
Čaňová, K., Rozýkyalová, L., Rudolf, E., 2017. Anthelmintic flubendazole and its potential use in anticancer therapy. Acta Medica Hiradek Kralove Czech Repub 60 (1), S–11.
Chassaing, C., Berger, M., Heckeroth, A., Ilg, T., Jaeger, M., Kern, C., Uphoff, M., 2008. Highly water-soluble prodrugs of anthelmintic benzimidazole carbamates: synthesis, pharmacodynamics, and pharmacokinetics. J. Med. Chem. 51 (5), 1111–1114.
Chen, L., Wang, L., Shen, H., Lin, H., Li, D., 2017. Anthelmintic drug niclosamide sensitizes the responsiveness of cervical cancer cells to paclitaxel via oxidative stress-mediated mTOR inhibition. Biochem. Biophys. Res. Commun. 484 (2), 416–421.
Jornada, D.H., dos Santos Fernandes, G.F., Chiba, D.E., De Melo, T.R.F., Dos Santos, J.L., Hou, Z.-J., Luo, X., Zhang, W., Peng, F., Cui, B., Wu, S.-J., Long, Z.-J., 2018. In vivo loss-of-function screens identify KPNB1 as a new drug target for HCV infection. Antimicrob. Agents Chemother. 62 (5), e00544-e00518.

Khalikov, S., Dushkin, A., 2020. Strategies for Solubility Enhancement of Anthelmintics. Pharm. Chem. J., 1–5

Kedma, M., Kodama, T., Noda, K., Matsumoto, E., Nakayama, H., Kobayashi, M., Hanash, S.M., Rangel, R., 2017. In vivo chemical sensitivity screens identify P2RY14 as a novel therapeutic target for Strongyloides infection. PLoS Negl. Trop. Dis. 11 (10), e0005762.

Kubota, K., 2015. Challenges and perspective of drug repurposing strategies in early stage clinical trials. Oncoscience 2 (6), 576.

Khalil, S., Dushkin, A., 2020. Strategies for Solubility Enhancement of Anthelmintics. Pharm. Chem. J., 1–5

Kedma, M., Kodama, T., Noda, K., Matsumoto, E., Nakayama, H., Kobayashi, M., Hanash, S.M., Rangel, R., 2017. In vivo chemical sensitivity screens identify P2RY14 as a novel therapeutic target for Strongyloides infection. PLoS Negl. Trop. Dis. 11 (10), e0005762.

Kubota, K., 2015. Challenges and perspective of drug repurposing strategies in early stage clinical trials. Oncoscience 2 (6), 576.

Khalil, S., Dushkin, A., 2020. Strategies for Solubility Enhancement of Anthelmintics. Pharm. Chem. J., 1–5

Kedma, M., Kodama, T., Noda, K., Matsumoto, E., Nakayama, H., Kobayashi, M., Hanash, S.M., Rangel, R., 2017. In vivo chemical sensitivity screens identify P2RY14 as a novel therapeutic target for Strongyloides infection. PLoS Negl. Trop. Dis. 11 (10), e0005762.

Kubota, K., 2015. Challenges and perspective of drug repurposing strategies in early stage clinical trials. Oncoscience 2 (6), 576.

Khalil, S., Dushkin, A., 2020. Strategies for Solubility Enhancement of Anthelmintics. Pharm. Chem. J., 1–5

Kedma, M., Kodama, T., Noda, K., Matsumoto, E., Nakayama, H., Kobayashi, M., Hanash, S.M., Rangel, R., 2017. In vivo chemical sensitivity screens identify P2RY14 as a novel therapeutic target for Strongyloides infection. PLoS Negl. Trop. Dis. 11 (10), e0005762.

Kubota, K., 2015. Challenges and perspective of drug repurposing strategies in early stage clinical trials. Oncoscience 2 (6), 576.

Khalil, S., Dushkin, A., 2020. Strategies for Solubility Enhancement of Anthelmintics. Pharm. Chem. J., 1–5

Kedma, M., Kodama, T., Noda, K., Matsumoto, E., Nakayama, H., Kobayashi, M., Hanash, S.M., Rangel, R., 2017. In vivo chemical sensitivity screens identify P2RY14 as a novel therapeutic target for Strongyloides infection. PLoS Negl. Trop. Dis. 11 (10), e0005762.

Kubota, K., 2015. Challenges and perspective of drug repurposing strategies in early stage clinical trials. Oncoscience 2 (6), 576.

Khalil, S., Dushkin, A., 2020. Strategies for Solubility Enhancement of Anthelmintics. Pharm. Chem. J., 1–5

Kedma, M., Kodama, T., Noda, K., Matsumoto, E., Nakayama, H., Kobayashi, M., Hanash, S.M., Rangel, R., 2017. In vivo chemical sensitivity screens identify P2RY14 as a novel therapeutic target for Strongyloides infection. PLoS Negl. Trop. Dis. 11 (10), e0005762.

Kubota, K., 2015. Challenges and perspective of drug repurposing strategies in early stage clinical trials. Oncoscience 2 (6), 576.
